C
Carmine Therapeutics
Developing novel types of gene therapies that utilize extracellular vesicles (EVs) produced in the laboratory
About Carmine Therapeutics
Carmine Therapeutics, headquartered in Cambridge, Massachusetts, is an innovative biotech company specializing in the development of next-generation gene therapies. The company leverages a unique technology based on red blood cell extracellular vesicles (RBCEVs). These vesicles are naturally produced by red blood cells and are devoid of genetic material, making them biocompatible and non-immunogenic, meaning they do not provoke an immune response. This is a significant advantage over traditional viral-based gene therapies, which often face challenges such as immune reactions, limited capacity for genetic material, and complex manufacturing processes.
Carmine Therapeutics' proprietary Red Cell EV Gene Therapy platform allows for the creation of a wide range of disease-modifying gene therapies. These therapies are designed to treat a broad spectrum of diseases by utilizing the modular nature of RBCEVs. The vesicles can be easily manipulated to load nucleic acids and modify their surfaces, making them highly adaptable for various therapeutic applications.
The company's business model focuses on research and development (R&D) to create these advanced gene therapies. Carmine Therapeutics collaborates with other biotech firms and pharmaceutical companies, such as Takeda, to co-develop and commercialize these therapies. Revenue is generated through partnerships, licensing agreements, and potentially through the direct sale of their proprietary therapies once they receive regulatory approval.
Carmine Therapeutics primarily serves clients in the healthcare and pharmaceutical sectors, including patients suffering from genetic disorders, healthcare providers, and other biotech companies looking for innovative gene therapy solutions. The market it operates in is the rapidly growing field of gene therapy, which aims to treat or prevent diseases by modifying the genetic material within a patient's cells.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Oct 2022 | $14M | $55M | Cystic Fibrosis Foundation · Evx Ventures · Huagai Capital · Simcere Pharma | ↗ |
| SUPPORT PROGRAM✓Other financing | Nov 2021 | $0 | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Carmine Therapeutics is 2.2K monthly website visits, up 129.2% over the last three months. Carmine Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Carmine Therapeutics in the Cambridge ecosystem
The Carmine Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
- EVEsco Ventures
Takeda
EVX Ventures
Series A3 investors entered at this stage
Huagai Capital
Cystic Fibrosis Foundation
Simcere Pharma
Other known investors3 additional known investors
City University of Hong Kong
National University of Singapore
Falling Walls Foundation
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Carmine Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Carmine Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










